Lifileucel肿瘤浸润淋巴细胞细胞疗法治疗晚期黑色素瘤患者的长期疗效与安全性:C-144-01研究的5年分析
C-144-01研究5年随访评估Lifileucel一次性自体肿瘤浸润淋巴细胞疗法在晚期黑色素瘤患者中的长期疗效与安全性。截至2024年11月20日,客观缓解率为31.4%(完全缓解5.9%,部分缓解25.5%),中位缓解持续时间36.5个月,中位总生存期13.9个月,5年总生存率19.7%。不良事件与非清髓性淋巴细胞清除和白介素-2的安全性特征一致。
要点
- 客观缓解率31.4%,其中完全缓解5.9%,部分缓解25.5%。
- 中位缓解持续时间36.5个月,31.3%的缓解者在5年评估时仍持续缓解。
- 中位总生存期13.9个月,5年总生存率19.7%。
核心结论
- 5年分析显示一次性Lifileucel治疗具有长期获益和有意义的總生存期,未发现新的长期安全性问题。
研究设计与样本
- C-144-01研究的5年随访分析,评估Lifileucel一次性自体肿瘤浸润淋巴细胞细胞疗法在晚期黑色素瘤患者中的长期疗效和安全性。
主要发现
- 截至2024年11月20日,客观缓解率为31.4%(完全缓解5.9%,部分缓解25.5%)。
- 79.3%的患者肿瘤负荷减小;16例缓解加深,其中4例在Lifileucel输注后超过1年由部分缓解转为完全缓解;31.3%的缓解者完成5年评估时仍持续缓解。
- 中位缓解持续时间为36.5个月。
- 缓解者(n=48)较总体人群肿瘤负荷更低、肝或脑转移更少。
- 中位总生存期为13.9个月,5年总生存率为19.7%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with advanced melanoma resistant to immune checkpoint or BRAF/MEK inhibitors have treatment options with relatively low efficacy. Lifileucel, a one-time autologous tumor-infiltrating lymphocyte cell therapy, was approved in the United States on the basis of the pivotal C-144-01 study. A 5-year follow-up of the C-144-01 trial assessed the long-term efficacy and safety of lifileucel. At the cutoff date (November 20, 2024), the objective response rate was 31.4% (complete response [CR], 5.9%; partial response [PR], 25.5%). Overall, 79.3% of patients had tumor burden reduction; 16 had deepened responses with four converting from PR to CR > 1 year after lifileucel infusion; 31.3% of responders completed the 5-year assessment with ongoing responses. The median duration of response was 36.5 months. Responders (n = 48) had lower tumor burden and fewer liver or brain metastases than the overall population. The median overall survival (OS) was 13.9 months, with a 5-year OS of 19.7%. Adverse events were consistent with nonmyeloablative lymphodepletion and interleukin-2 safety profiles and declined rapidly within 2 weeks after lifileucel infusion. Most grade 3/4 cytopenias resolved to grade ≤2 by day 30. This 5-year analysis demonstrated long-term benefit and meaningful OS with one-time lifileucel therapy, with no additional long-term safety concerns.
引用
- Medina T, Chesney JA, Kluger HM, et al. Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study. J Clin Oncol. 2025. PMID: 40454684. doi:10.1200/JCO-25-00765
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。